About
Genome Editing Therapies (CRISPR)
Areas of Focus
Categories
Boston & New England
Clinical Trials (7)
View allTotal Trials
7
As Lead Sponsor
6
As Collaborator
1
Total Enrollment
418
By Phase
PHASE3: 1NA: 1PHASE1/PHASE2: 3
By Status
ENROLLING_BY_INVITATION: 2ACTIVE_NOT_RECRUITING: 2RECRUITING: 1UNKNOWN: 1COMPLETED: 1
Clinical Trials Pipeline7 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
2033
2034
2035
2036
2037
2038
2039
2040
2041
Today
Hover over trial bars to see details
Recent Trials
NCT06950190Lead Sponsor
Evaluating Cognitive Changes on Patients in Chemotherapy (ECCPC)
PHASE3Enrolling by invitation
100 participants
Started: Jun 9, 2025 · Completed: Feb 20, 2027
NCT06363760Lead Sponsor
A Long-Term Follow-Up Study of Participants With Sickle Cell Disease or Transfusion Dependent β-Thalassemia Who Received EDIT-301
N/AEnrolling by invitation
54 participants
Started: Jun 17, 2024 · Completed: Aug 31, 2040
NCT06752512Collaborator
Remote Temperature Monitoring of Patients At Risk for Developing Fever
NARecruiting
150 participants
Started: Aug 9, 2023 · Completed: Jan 31, 2025
NCT05444894Lead Sponsor
EDIT-301 for Autologous Hematopoietic Stem Cell Transplant (HSCT) in Participants With Transfusion-Dependent Beta Thalassemia (TDT)
PHASE1/PHASE2Active, not recruiting
9 participants
Started: Apr 29, 2022 · Completed: Dec 31, 2025
NCT04853576Lead Sponsor
A Study Evaluating the Safety and Efficacy of EDIT-301 in Participants With Severe Sickle Cell Disease (RUBY)
PHASE1/PHASE2Active, not recruiting
45 participants
Started: May 4, 2021 · Completed: Aug 31, 2025
Locations (1)
Headquarters
Cambridge, MA, United States
Map
Loading map...